# China NMPA Drug Inspection - Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd. - Sanqi Wound Medicine Tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-province-cross-sea-biochemical-pharmaceutical-manufacturing-co-ltd/0bd3808f-14e6-46c6-8e46-67ed3b4472f4/
Source feed: China

> China NMPA drug inspection for Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd. published March 01, 2017. Drug: Sanqi Wound Medicine Tablets. The Sichuan Provincial Food and Drug Administration issued its "2017 First Issue Sichuan Provincial Drug Quality Bulleti

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Provincial Food and Drug Administration's First Issue of Sichuan Provincial Drug Quality Bulletin in 2017
- Company Name: Jilin Province Cross-Sea Biochemical Pharmaceutical Manufacturing Co., Ltd.
- Publication Date: 2017-03-01
- Drug Name: Sanqi Wound Medicine Tablets
- Inspection Finding: Properties
- Action Taken: The announcement stated that the drugs were substandard.
- Summary: The Sichuan Provincial Food and Drug Administration issued its "2017 First Issue Sichuan Provincial Drug Quality Bulletin" on February 14, 2017, publicly announcing findings from drug supervision and sampling inspections. Conducted under the "2016 Provincial Drug Sampling Inspection Work Plan," these inspections targeted various drug production, distribution, and use units across the province. The bulletin identified 20 batches of substandard drugs from multiple manufacturers. Key violations included quality control issues such as "Filling Weight Difference" (e.g., Gengnian'an Capsules by Diaoyutai Pharmaceutical Group Jilin Tianqiang Pharmaceutical Co., Ltd.) and general "Weight Difference" for several preparations. Other significant deficiencies included deviations in "Properties" (e.g., Yangxue An Shenpian by Shandong Luyao Pharmaceutical Co., Ltd. and Agastache Gas and Water by Sichuan Rainbow Pharmaceutical Co., Ltd.), "Dissolution" failures for Berberine Tablets (e.g., Changchun Changhong Pharmaceutical Co., Ltd. and Shenzhen Gaozhuo Pharmaceutical Co., Ltd.), and issues with "pH Value" (Lobata Hydrochloride Injection by China Resources Shuanghe Pharmaceutical Co., Ltd.). "Moisture," "Extractives," "Uniformity," and "Packaging Difference" were also reported. The regulatory framework for these findings is based on the Chinese Pharmacopoeia and Ministry of Health Drug Standards. The bulletin serves to inform the public and industry, implying that the listed companies must address these quality control deficiencies to ensure compliance with drug quality standards.

Company: https://www.globalkeysolutions.net/companies/jilin-province-cross-sea-biochemical-pharmaceutical-manufacturing-co-ltd/9c4b658a-97ca-455e-b9e9-6ca01e55ff1b/